In melanoma, it is known to drive the production of Interleukin-1 beta (IL-1β), which sustains chemotherapy-resistant cells through an IL-1β/Interleukin-8 (IL-8)/C-X-C motif Chemokine Receptor 1 (CXCR1) signaling circuit, establishing a response that reinforces tumor growth and survival. Here, IL1B is linked to neoplasm.